{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:00:27Z","timestamp":1792623627324,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This report describes the case of a 48-year-old woman who presented with sternoclavicular joint arthritis after administration of an immune checkpoint inhibitor (ICI), durvalumab, for small cell lung carcinoma. The onset of arthritis transpired 18 months after the commencement of the ICI therapeutic regimen and demonstrated resilience to glucocorticoid treatment. After excluding infectious aetiologies and metastatic involvement, the patient was diagnosed with ICI-induced arthritis (ICI-IA). Considering the articular implications akin to the SAPHO syndrome, the patient was treated with infliximab, resulting in complete resolution. This finding implies that biological DMARDs can serve as effective interventions for ICI-induced sternoclavicular joint arthritis. Given the heterogeneous nature of its pathogenesis, the selection of therapeutic agents may require customization based on the distinct clinical presentation of each individual case.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1400097","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:47:33Z","timestamp":1715316453000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Inflammatory sternoclavicular joint arthritis induced by an immune checkpoint inhibitor with remarkable responsiveness to infliximab"],"prefix":"10.3389","volume":"15","author":[{"given":"Shion","family":"Kachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Sumitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheumatol Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheumatol Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/art.41036","article-title":"A rare side effect of checkpoint inhibitor therapy: Nivolumab induced axial polyarthritis of the facet and costovertebral joints","volume":"71","author":"Feist","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12832","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis","volume":"294","author":"Cappelli","year":"2020","journal-title":"Immunol Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"kead438","DOI":"10.1093\/rheumatology\/kead438","article-title":"Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis","author":"Cappelli","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.90B6.20391","article-title":"Disorders of the sternoclavicular joint","volume":"90","author":"Robinson","year":"2008","journal-title":"J Bone Joint Surg Br"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex470","article-title":"Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events","volume":"57","author":"Albayda","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.crad.2011.08.014","article-title":"SAPHO: What radiologists should know","volume":"67","author":"Depasquale","year":"2012","journal-title":"Clin Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.006","article-title":"Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors","volume":"106","author":"de Malet","year":"2019","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheumatol Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"ltad011","DOI":"10.1093\/immadv\/ltad011","article-title":"Blockade of innate inflammatory cytokines TNFalpha, IL-1beta, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression","volume":"3","author":"Walsh","year":"2023","journal-title":"Immunother Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.972","article-title":"846P Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial","volume":"33","author":"Meyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheumatol Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04675-2","article-title":"SAPHO: has the time come for tailored therapy","volume":"39","author":"Figueiredo","year":"2020","journal-title":"Clin Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1400097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:47:35Z","timestamp":1715316455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1400097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2024.1400097"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1400097","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"article-number":"1400097"}}